---
run_id: halo-evidence-vs-diagnosis-validation-v7-famous-sources-supplied-02
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: famous_sources_supplied
run_number: 2
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 202
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
condition_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
output_file: model-outputs/famous_sources_supplied-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `famous_sources_supplied`, run 2 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 202, on the frozen condition packet.

## Output

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a classic "Halo Effect": the board is attributing a rise in NRR to strategic discipline and product-market fit, when the data suggests the growth is artificial. The revenue bump is primarily a result of financial engineering (six-month discounts) and sales influence (telling customers the feature is a priority) rather than organic value creation.

Crucially, the product is failing the "pragmatist" user. While "champions" (early adopters) are using the tool for enablement, the front-line reviewers—the people whose daily workflow the product is designed for—have a dismal 31% retention rate. Furthermore, the "faster ticket closure" in support is a vanity metric, as product failures are being reclassified as training gaps. Scaling now would be "scaling a leak," committing heavy resources to a product that hasn't yet crossed the chasm from "champion toy" to "essential workflow tool." The evidence pass is the only option that separates the signal (actual utility) from the noise (discount-driven renewals).

**The Strongest Reason Against It**
The primary risk is political and temporal. The board is currently in a state of high confidence and "upbeat" sentiment. By pausing discounts and slowing the sales momentum to "instrument behavior," you are effectively popping a bubble. This may be perceived by the CEO and Sales leadership as a lack of confidence or a failure to "strike while the iron is hot," potentially jeopardizing the budget or the perceived momentum of the product team in the eyes of the board.

**Observable Evidence That Would Change My Mind**
I would pivot to "Scale Broadly" if the "non-renewal letters" from the regional banks are proven to be administrative procurement delays rather than product dissatisfaction, AND if the 31% front-line retention rate shows a statistically significant upward trend in accounts that *did not* receive the "strategic-feature pitch" or discounts. If the product is pulling in users organically without the "push" from account managers, the "wedge" is real and the risk of scaling is mitigated.
